Beta Blockers for the Prevention of Acute Exacerbations of COPD
Abstract
We conducted a multicenter, randomized, placebo-controlled trial to definitively assess the impact of metoprolol succinate on the rate and severity of COPD exacerbations. We completed the primary project early, and the New England Journal of Medicine published our finding in October 2019. The results strongly indicate that patients with COPD and at risk for exacerbation should not be prescribed beta-blockers in the absence of an established indication for the drugs such as recent myocardial infarction or heart failure. These results raise important questions about the use of beta- blockers in patients with COPD and myocardial infarction. To address these questions and bolster the findings of the primary project, we are conducting an observational study of beta-blockers in patients with COPD and myocardial infarction as an additional task to the approved statement of work. Major activities for this reporting period centered on concluding enrollment and follow-up at all clinical sites.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1194708
Entities
People
- Mark T Dransfield
Organizations
- University of Alabama